Correlation Between Evogene and Protalix Biotherapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Evogene and Protalix Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Evogene and Protalix Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Evogene and Protalix Biotherapeutics, you can compare the effects of market volatilities on Evogene and Protalix Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Evogene with a short position of Protalix Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Evogene and Protalix Biotherapeutics.

Diversification Opportunities for Evogene and Protalix Biotherapeutics

-0.82
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Evogene and Protalix is -0.82. Overlapping area represents the amount of risk that can be diversified away by holding Evogene and Protalix Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Protalix Biotherapeutics and Evogene is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Evogene are associated (or correlated) with Protalix Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Protalix Biotherapeutics has no effect on the direction of Evogene i.e., Evogene and Protalix Biotherapeutics go up and down completely randomly.

Pair Corralation between Evogene and Protalix Biotherapeutics

Given the investment horizon of 90 days Evogene is expected to under-perform the Protalix Biotherapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Evogene is 1.5 times less risky than Protalix Biotherapeutics. The stock trades about -0.45 of its potential returns per unit of risk. The Protalix Biotherapeutics is currently generating about 0.37 of returns per unit of risk over similar time horizon. If you would invest  108.00  in Protalix Biotherapeutics on August 26, 2024 and sell it today you would earn a total of  61.00  from holding Protalix Biotherapeutics or generate 56.48% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Evogene  vs.  Protalix Biotherapeutics

 Performance 
       Timeline  
Evogene 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Evogene has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.
Protalix Biotherapeutics 

Risk-Adjusted Performance

17 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Protalix Biotherapeutics are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain essential indicators, Protalix Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Evogene and Protalix Biotherapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Evogene and Protalix Biotherapeutics

The main advantage of trading using opposite Evogene and Protalix Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Evogene position performs unexpectedly, Protalix Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protalix Biotherapeutics will offset losses from the drop in Protalix Biotherapeutics' long position.
The idea behind Evogene and Protalix Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Other Complementary Tools

Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios